Nascent Announces the Completion of Its Phase 1 Clinical Trials
NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
NASCENT BIOTECH NEWS
